SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 2008175
• 负责人: Glenn M Mills
• 金额: $ 6.92万
• 依托单位: LOUISIANA STATE UNIV HSC SHREVEPORT
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-04-01 至 1997-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2008175
• 关键词: acute leukemia; bone marrow transplantation; breast neoplasms; cancer information system; clinical trials; colon neoplasms; combination cancer therapy; combination chemotherapy; cooperative study; ethnic group; female reproductive system neoplasm; gastrointestinal neoplasms; head /neck neoplasm; human subject; human therapy evaluation; immunomodulators; levamisole; lung neoplasms; lymphocyte; lymphoma; lysosomes; membrane proteins; multiple myeloma; natural killer cells; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; sarcoma; surface antigens; tumor antigens; urinary tract neoplasms

Louisiana State University Schools of Medicine (LSU) in New Orleans and in Shreveport (LSU-NO and LSU-S) are applying for grant support to participate in the clinical trials and scientific research programs of the Southwest Oncology Group. LSU-NO has been a Group member since 1965 with LSU-S joining as a co-member in 1982. Although currently not funded, LSU has continued as an active Group member, enrolling a record number of patients. From October 1, 1990, to September 30, 1991, (period reported in the continuing application of the Group) LSU registered 167 patients compared to 73 in the same period in 1987-88. This 129 percent increase in accrual has been possible by an institutional commitment to improve the care of the indigent and minority patients who make up almost all the patients seen at our centers and by participation in the UCOP, High Priority, and CTEP Minority Initiative Programs. LSU has recruited a record number of Group members from all cancer care specialties emphasizing a multimodality approach to cancer care. By concentrating our resources, we have become one of the top UCOP programs in the country with 55 enrollments this period and one of the leading registrants to both the CTEP Minority Initiatives and the High Priority Programs. Quality data has been consistently submitted with our quality ranking being above average. With full grant funding we plan to: 1) expand availability of clinical trials to indigent and minority patients in other areas of the state by opening satellites at four regional hospitals supervised by LSU-S or LSU-NO, 2) enhance CGOP accrual by providing full data management support, and 3) and continue accruing a high number of patients while maintaining the quality of data. LSU has overcome past criticisms of limited patient accrual and shown the capability of being a major Group participant.

路易斯安那州立大学医学院（LSU）在新奥尔良， 在Shreveport（LSU-NO和LSU-S），正在向 参加临床试验和科学研究计划 西南肿瘤学小组。 LSU-NO自1965年以来一直是小组成员 LSU-S于1982年加入合伙人。虽然目前没有 LSU资助了，继续担任活跃的小组成员，注册记录 患者数量。 从1990年10月1日到1991年9月30日（时期） LSU注册的LSU持续申请中报告了167 患者在1987 - 88年的同一时期为73例。 这129％ 机构承诺可能会增加应计的增长 改善几乎构成贫困和少数族裔患者的护理 所有在我们中心看到的患者，并参与UCOP， 高优先事项和CTEP少数派倡议计划。 LSU已招募 所有癌症护理专业的小组成员人数创纪录 强调一种多模式的癌症护理方法。 通过集中精力 我们的资源，我们已成为该国顶级的UCOP计划之一 该期间有55次入学人数，其中一位是领先的注册人 CTEP少数派倡议和高优先级计划。 质量数据一直始终与我们的质量排名一起提交 高于平均水平。 通过全额赠款，我们计划：1）扩展 在贫困患者和少数族裔患者的临床试验中可用性 该州的其他地区通过在四家地区医院开设卫星 由LSU-S或LSU-NO监督，2）通过提供完整来增强CGOP应计 数据管理支持和3）并继续获得大量 在保持数据质量的同时。 LSU克服了过去 批评有限的患者应计的批评，并表明了成为 主要小组参与者。